Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Vigabatrin is a medication used to treat epilepsy. It became available as a generic medication in 2019. It works by inhibiting the breakdown of γ-aminobutyric acid (GABA). It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors.
Market Analysis and Insights: Global Vigabatrin Market
The global Vigabatrin market is valued at US$ XX million in 2019. The market size will reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
Global Vigabatrin Scope and Market Size
Vigabatrin market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Vigabatrin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.
Segment by Type
Tablet
Powder
Segment by Application
Infantile Spasms (IS)
Partial-Onset Seizures
Refractory Complex Partial Seizures
By Company
Sanofi
Benta Pharma Industries
Dr. Fisher Farma
Lundbeck
Novartis
Perrigo
Grindeks
Endo International
Amneal Pharma
Cipla
Upsher-Smith
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
Market Analysis and Insights: Global Vigabatrin Market
The global Vigabatrin market is valued at US$ XX million in 2019. The market size will reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
Global Vigabatrin Scope and Market Size
Vigabatrin market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Vigabatrin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.
Segment by Type
Tablet
Powder
Segment by Application
Infantile Spasms (IS)
Partial-Onset Seizures
Refractory Complex Partial Seizures
By Company
Sanofi
Benta Pharma Industries
Dr. Fisher Farma
Lundbeck
Novartis
Perrigo
Grindeks
Endo International
Amneal Pharma
Cipla
Upsher-Smith
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
